Syngeneic hematopoietic stem cell transplantation for women with metastatic breast cancer

Bone Marrow Transplantation

Volumn 32, Issue 2, 2003, Pages 151-155

  Rizzo, J D ^a   Williams, S ^b   Wu, J T ^a   Pecora, A L ^c   Lazarus, H M ^d   Bolwell, B ^e   Fields, K K ^f   Gale, R P ^g   Elfenbein, G ^h   Horowitz, M M ^a   Antman, K H ⁱ  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Hematology Oncology Associates of Illinois   (United States)

^c HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^g Center for Advanced Studies in Leukemia   (United States)

^h ROGER WILLIAMS MEDICAL CENTER   (United States)

ⁱ Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Breast cancer; Hematopoietic stem cell transplantation; Syngeneic

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; MELPHALAN; PACLITAXEL; PLATINUM; TAMOXIFEN; THIOTEPA;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOGRAFT; AUTOTRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; ISOGRAFT; MASTECTOMY; METASTASIS; MINIMAL RESIDUAL DISEASE; MONOZYGOTIC TWINS; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MASTECTOMY; MIDDLE AGED; NEOPLASM METASTASIS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION, ISOGENEIC; TREATMENT OUTCOME; TWINS, MONOZYGOTIC;

EID: 10744226696     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704120     Document Type: Article

References (18)

1. Berry DA, Broadwater G, Klein JP et al. High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2002; 20: 743-750.
2. Stadtmauer EA, O'Neill A, Goldstein LJ et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med 2000; 342: 1069-1076.
3. Peters WP, Jones RB, Vredenburgh J et al. A large, prospective, randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based initial therapy (AFM). Breast Cancer Treat Res 1996; 37: 35.
4. Lotz JP, Cure H, Janvier F et al. High dose chemotherapy (HD-CT) with hematopoietic stem cells transplantation (HSCT) for metastatic breast cancer (MBC): Results of the French protocol PEGASE 04. Proc Am Soc Clin Oncol 1999; 17: 2a.
5. Madan B, Broadwater G, Rubin P et al. Improved survival with consolidation high-dose cyclophosphamide, cisplatin and carmustine (CPB) compared with observation in women with metastatic breast cancer (MBC) and only bone metastases treated with induction adriamycin, 5-fluorouracil and methotrexate (AFM): A phase III prospective randomized comparative trial. Proc Am Soc Clin Oncol 2000; 10: 48a.
6. Crump M, Gluck S, Stewart D et al. A randomized trial of high-dose chemotherapy (HDC) with autologous peripheral blood stem cell support (ASCT) compared to standard therapy in women with metastatic breast cancer: a National Cancer Institute of Canada (NCIC) Clinical Trials Group Study. Proc Am Soc Clin Oncol 2001; 20: 82a.
7. Rowlings PA, Williams SF, Antman KH et al. Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. JAMA 1999; 282: 1335-1343.
8. Peters W, Rosner G, Vredenburgh J et al. for CALGB, SWOG, and NCIC. A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. Proc Am Soc Clin Oncol 1999; 18: 1a.
9. Bergh J, Wiklund T, Erikstein B et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial, Scandinavian Breast Group 9401 study. Lancet 2000; 356: 1384-1391.
10. Ross AA, Cooper BW, Lazarus HM et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82: 2605-2610.
11. Solano C, Badia B, Lluch A et al. Prognostic significance of the immunocytochemical detection of contaminating tumor cells (CTC) in apheresis products of patients with high-risk breast cancer treated with high-dose chemotherapy and stem cell transplantation. Bone Marrow Transplant 2001; 27: 287-293.
12. Fields KK, Elfenbein GJ, Trudeau WL et al. The clinical significance of bone marrow metastases as detected using polymerase chain reaction methods in patients with breast cancer undergoing high-dose chemotherapy with autologous bone marrow transplantation. J Clin Oncol 1996; 14: 1868-1876.
13. Shpall EJ, Jones RB, Bearman SI et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy. J Clin Oncol 1994; 12: 28-36.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
15. Pepe MS, Mori M. Kaplan-Meier. Marginal or conditional probability curves in summarizing competing risk failure time data? Stat Med 1993; 12: 187-200.
16. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data. Springer: Berlin, 1997.
17. Antman KH, Rowlings PA, Vaughan WP et al. High-dose chemotherapy with autologous hematopoietic stem cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870-1879.
18. + hematopoietic stem cells in patients with metastatic breast cancer. Biol Blood Marrow